Phase 2 N=26 Intranasal Insulin for Weight Management During Smoking Cessation
Tobacco Abstinence Syndrome
Primary: Amount Eaten in Taste Test — 124; 116 grams
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome
Tobacco Abstinence Syndrome
Primary: Episodic Memory — 11.6; 10.0 number of words recalled
Phase 2 N=3 Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
Scalp Psoriasis
Primary: Number of Participants With HPA Axis Suppression — 0; 2 Participants
Phase 2 N=224 Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Percentage of Participants With Complete Clearance of Actinic Keratosis Lesions (AKs) — 12.7; 5.1; 26.8; 0.0 percentage of participants — p=0.18
Phase 2 N=98 A Study of A-101 Solution in Subjects With Common Warts.
Common Warts
Primary: Efficacy Based on Mean Change in Physician Wart Assessment Over Time — -0.38; -1.00; -0.44 units on a scale — p=0.555
Phase 2 N=172 Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
Seborrheic Keratosis
Primary: Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA) — 4.82; 26.79; 45.09 percentage of lesions cleared — p=0.0003
Phase 2 N=28 An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
Atopic Dermatitis
Primary: The Number of Patients in the Study With HPA Axis Suppression — 8; 9 Participants
Phase 2 N=130 Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery
Atrial Fibrillation
Primary: Time to In-hospital Post-operative Atrial Fibrillation (POAF) — 224.38; 194.76 hours — p=0.18
Phase 2 N=26 Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants With HPA Axis Suppression — 3; 0; 21; 1 Participants
Phase 2 N=20 Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
IgG4-RD
Primary: Proportion of Patients With an Improvement in IgG4-RD Activity — 12; 4; 2; 0 Participants
Phase 2 N=24 Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
Dermatitis, Atopic
Primary: Number of Participants With HPA Axis Suppression — 3; 1; 16; 3 Participants
Phase 2 N=218 Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change in BCVA at Week 24 — 5.2; 2.7; -1.5; 7 Letters on ETDRS eye chart
Phase 2 N=86 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Response Rate — 18; 34; 28 percentage of participants
Phase 2 N=100 A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology (ACR)50 Response at Week 16 — 11.4; 14.3; 2.9 Percentage of Participants — p=0.178
Phase 2 N=24 Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS
Psoriasis
Primary: Proportion of Patients in the Study With HPA Axis Suppression — 1; 13 Participants